WHAT IS REGEN-D 60-150 RECOMBINANT HUMAN EPIDERMAL GROWTH FACTOR GEL
Regen-D contains skin growth hormones Ranitidine / Dicyclomine / Simethicone that act on the skin cells to encourage rapid reproduction and natural strengthening. This makes it useful for those who have recently had a skin graft operation or a recent injury causing abrasion or an open wound. It has also shown effectiveness for rejuvenation of the skin for cosmetic reasons. Your dermatologist may prescribe this medication for the treatment of other unlisted conditions, as well.
Regen-D 60-150 (Epidermal Growth Factor) is a topical gel prescribed to those who require rapid regrowth or strengthening of the skin for a variety of reasons. Regen-D 60mg or 150mg is an alternative to Regranex Gel, contains growth hormones rhEGF (Ranitidine / Dicyclomine / Simethicone) that act on the skin cells to encourage rapid reproduction and natural strengthening. This makes it useful for those who have recently had a skin graft operation or a recent injury causing abrasion or an open wound. It has also shown effectiveness for rejuvenation of the skin for cosmetic reasons. Your dermatologist may prescribe this medication for the treatment of other unlisted conditions, as well.
Regen-D 60-150 ® is Human Epidermal Growth Factors rhEGF produced by recombinant technology and is a new generation therapy with a novel factor used for first and second degree burns, skin grafts, and bed sores. Regen-D 60-150 ® has been widely researched and documented with published data and an International patent as well. Regen-D 60 ® Gel regenerates faster and halves the healing time took first & second-degree burns, skin grafts and bed sores. Regen-D ® was awarded an Innovation Award by Marico Foundation World for its product and process innovation.
Recombinant human epidermal growth factor (REGEN-D 150), which was cloned and overexpressed in E. coli, has shown enhanced healing of chronic diabetic foot ulcers (DFU) by significantly reducing the duration of healing in addition to providing excellent quality of wound healing and re-epithelization. Post-marketing surveillance (PMS) study of REGEN-D 150 in 135 patients of DFU was compared with Phase III clinical trial data of REGEN-D 150. Statistical analysis of study data determined that the empirical survival probability distribution, in terms of non-healing of ulcers, was lowest in the case of PMS study, better than that for Phase III; more DFU patients were healed in PMS study. Percentage of patients cured in any given week (e.g., in week 10) is above 90% in PMS study, as compared to 69% in Phase III clinical trial; this percentage was around 18% for the control group with placebo in the Phase III trial. The average wound healing time was significantly lower in PMS study, 4.8 weeks, while it was 9 weeks in Phase III clinical trials while the average wound healing with REGEN-D 150 was found to be 86% in this study. REGEN-D 150 has been found to result in healthy granulation and stimulate epithelization, thus leading to final wound closure. The PMS study has established the efficacy of REGEN-D 150 in faster healing of diabetic foot ulcers.
Healing effect of recombinant human epidermal growth factor (EGF) on chronic diabetic foot ulcers shown in this article. A total of 89 patients (65 male and 24 female) aged from 36 to 82 years (average of 54) enrolled for the prospective, open-label trial, crossover study. Predetermined criteria were used for diagnosis and classification of ulcer. The average duration of ulcer was 6 months (range from 3 to 27 months) prior to study. Upon study, the ulcers were debrided and treated with hydrocolloid or composite dressing depending on the condition of the wound. If treatment effect was minimal using advanced dressing for 3 weeks, patients were crossed over to twice-a-day treatment with 0.005% EGF and advanced dressing. Among the patients, 21 patients showed improvement using hydrocolloid or composite dressing alone and 68 patients were crossed over to treatment with EGF and advanced dressing. In the EGF-treated patients, complete healing was noted in 52 patients within an average of 46 days (range from 2 to 14 weeks). Recurrence was not noted during the 6-month observation. But 5 patients showed new lesions different from the prior site. Sixteen patients required further interventions. This paper suggests that topical treatment with EGF combined with advanced dressing may have positive effects in promoting the healing of chronic diabetic foot wounds.
HOW TO USE REGEN-D 60-150 RECOMBINANT HUMAN EPIDERMAL GROWTH FACTOR GEL
Regen-D (Recombinant Human Epidermal Growth Factor) should be used according to the instructions provided by your doctor and included with the packaging to get the most effective results from treatment. Regen-D 60-150 (Epidermal Growth Factor) Gel is normally applied once each day, but your individual directions will depend on your age, weight, health condition, and the severity of your symptoms. To apply the Regen-D 60 Gel gently rinse and dry the area to remove any dirt or loose skin, apply a small amount of cream, and gently massage it into the skin if possible. Leave the area being treated open to the air following each administration to allow any excess medication to evaporate. Wash your hands using soap and water after each application to prevent it from contacting any mucous membranes or areas not being treated.
SIDE EFFECTS OF REGEN-D 60-150 RECOMBINANT HUMAN EPIDERMAL GROWTH FACTOR GEL
- Mild stinging or burning sensations
- Dry, flaking, or peeling skin
- Slight redness or discoloration
- Discoloration of the skin
Stop using the medication and contact your dermatologist immediately if you experience any serious side effects such as severe pain or signs of an allergic reaction such as hives, skin rashes, swelling, or difficulty breathing. These conditions may require reduced application frequency or immediate medical attention in serious cases to prevent further health problems from occurring.
Regen-D 60-150 (Recombinant Human Epidermal Growth Factor) should not be used by users with a history of allergic reactions to similar conditions. You are also suggested to have your dermatologist perform a health check before beginning use of the Regen-D 60 Gel to ensure you do not have any chronic health conditions that may cause unexpected complications.
Strictly use Regen-D 60-150 Gel (Recombinant Human Epidermal Growth Factor) as prescribed and follow all instructions provided by your doctor. Regen-D 60 (Recombinant Human Epidermal Growth Factor) may not be safe or suitable for everyone. Always ensure your dermatologist is informed if you are pregnant or breastfeeding, using any other type of medication (including non-prescription medicine, vitamins, and supplements), as well as if you have any allergies, other illnesses, or pre-existing medication conditions.
Regen-D Gel is indicated for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply when used as an adjunct to, and not a substitute for, good ulcer care practices.
The efficacy of Regen-D Gel has not been established for the treatment of pressure ulcers and venous stasis ulcers.
The effects of Regen-D Gel on exposed joints, tendons, ligaments, and bone have not been established in humans.
Regen-D Gel is a non-sterile, low bioburden preserved product. Therefore, it should not be used in wounds that close by primary intention. Malignancies distant from the site of application have been reported in both a clinical study and in postmarketing use. The benefits and risks of Regen-D Gel treatment should be carefully evaluated before prescribing in patients with known malignancy.